依托芬林,Etofylline clofibrate,99.77%
产品编号:Bellancom-107348| CAS NO:54504-70-0| 分子式:C19H21ClN4O5| 分子量:420.85
Etofylline clofibrate 具有降脂和抗血栓形成作用。Etofylline clofibrate 具有与内膜 PGI2 激动的相互作用。
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
依托芬林
产品介绍 | Etofylline clofibrate 具有降脂和抗血栓形成作用。Etofylline clofibrate 具有与内膜 PGI2 激动的相互作用。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | Etofylline clofibrate has ypolipidemic and antithrombotic effect. Etofylline clofibrate has an agonistic interaction with intimal PGI2. | ||||||||||||||||
体外研究 | |||||||||||||||||
体内研究 |
Etofylline clofibrate (p.o.; 12 mg/kg) has the moderate effect of a single dose (12% reduction in disaggregation time) and has a maximum reduction of 31 and 43% following 5 and 7 consecutive daily applications, respectively. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
Etofylline clofibrate (p.o.; 12 mg/kg) has the moderate effect of a single dose (12% reduction in disaggregation time) and has a maximum reduction of 31 and 43% following 5 and 7 consecutive daily applications, respectively. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 52 mg/mL (123.56 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
参考文献 |
~82% ![]() 54504-70-0 |
文献:Metz; Specker Arzneimittel-Forschung/Drug Research, 1980 , vol. 30, # 116 p. 2014 - 2019 |

匹配竞争对手的价格

效率为先

专业经验 贴心服务

50000+库存